Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Naproxen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 1.00 |
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 11/20 | 1.00 |
| ▸ | AKR1C2 | P52895 | 11/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | CDC42 | P60953 | 1/20 | 1.00 |
| ▸ | RAC1 | P63000 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.65 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naproxen SCHEMBL29360045 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL215236 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL29350675 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL28834409 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL616149 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL42434 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL29359528 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL3046 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL10029028 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR | |
| Naproxen SCHEMBL30346195 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS2PTGS1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 467 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025226751-A1 | DARK-FIELD ABSORBANCE CIRCULAR DICHROISM OF ORIENTED CHIRAL THIN FILMS | PURDUE RESEARCH FOUNDATION (US) | 2025-10-30 | — | — | WO | claimed |
| WO-2025101983-A1 | NON-STEROIDAL ISONITRILE BINDING COMPOUNDS OF CYTOCHROME P450 SUBTYPES | BRANDEIS UNIVERSITY (US) | 2025-05-15 | — | — | WO | claimed |
| US-20250109171-A1 | COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL DISEASES | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2025-04-03 | — | — | US | claimed |
| US-20250084395-A1 | ENGINEERED NITRILASES FOR BIOCATALYSIS | KCAT ENZYMATIC PRIVATE LIMITED (IN) | 2025-03-13 | — | — | US | claimed |
| WO-2024201281-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF PAIN | WONDERFEEL (US) | 2024-10-03 | — | — | WO | claimed |
| CN-118579795-A | Drug controlled release system for S-configuration drug selective loading and having pH and glutathione dual response | 常州大学 | 2024-09-03 | — | — | CN | claimed |
| EP-4373836-A1 | COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL DISEASES | Shanghai MicuRx Pharmaceutical Co., Ltd. (CN) | 2024-05-29 | — | — | EP | claimed |
| CN-115322099-B | Naproxen-cinnamic acid derivative and application thereof in preparation of medicines for treating LPS-induced inflammation | 五邑大学 | 2024-04-02 | — | — | CN | claimed |
| CN-115028553-B | Preparation method of chiral N-Boc/Cbz-cis- (1R, 2S) -cyclohexanediamine | 上海瀚鸿科技股份有限公司 | 2024-03-26 | — | — | CN | claimed |
| EP-3752201-B1 | SUSPENSION OF NANOSCALE, ORGANIC PARTICLES AND PROCESS FOR PRODUCTION THEREOF | UNIV FRIEDRICH ALEXANDER ER (DE) | 2023-11-22 | — | — | EP | claimed |
| US-11634443-B2 | Treprostinil prodrugs | UNITED THERAPEUTICS CORPORATION (US) | 2023-04-25 | — | — | US | claimed |
| US-11590095-B2 | Fumarate ester dosage forms | BANNER LIFE SCIENCES LLC (US) | 2023-02-28 | — | — | US | claimed |
| WO-2023001223-A1 | COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL DISEASES | SHANGHAI MICURX PHARMACEUTICAL CO., LTD. (CN) | 2023-01-26 | — | — | WO | claimed |
| CN-115322099-A | Naproxen-cinnamic acid derivatives and application thereof in preparation of drugs for treating LPS (LPS) -induced inflammation | 五邑大学 | 2022-11-11 | — | — | CN | claimed |
| CN-115028553-A | Preparation method of chiral N-Boc/Cbz-cis- (1R,2S) -cyclohexanediamine | 上海瀚鸿科技股份有限公司 | 2022-09-09 | — | — | CN | claimed |
| CN-111999416-B | Method for resolving R/S-N-Boc-piperidinol by chiral derivative reagent pre-column derivatization high performance liquid chromatography | 上海柏狮生物科技有限公司 | 2022-08-26 | — | — | CN | claimed |
| CN-111056939-B | Preparation method of (1R,3S) -3-aminocyclopentanol and intermediate thereof | 弈柯莱生物科技(上海)股份有限公司 | 2022-08-05 | — | — | CN | claimed |
| US-20220168432-A1 | MODIFIED RELEASE FORMULATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES | PROVIDENT BANK | 2022-06-02 | — | — | US | claimed |
| CN-114457055-A | Carboxylesterase, coding gene, genetically engineered bacterium and application thereof | 浙江工业大学 | 2022-05-10 | — | — | CN | claimed |
| CN-114394983-A | Synthesis of polycyclic carbamoylpyridone compounds | 吉利德科学公司 | 2022-04-26 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11590095-B2 | Fumarate ester dosage forms | FH, FAH, SDHB | PTGS2 1779/4885PTGS1 1350/4885AKR1C3 477/4885 |
| US-20250109171-A1 | COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF RENAL DISEASES | REN, VHL, RCC2 | PTGS2 3865/4885PTGS1 3460/4885AKR1C3 532/4885 |
| US-11634443-B2 | Treprostinil prodrugs | TYMP, TK1, DCTPP1 | PTGS2 203/4885PTGS1 127/4885AKR1C3 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.